Zhiwei “George” Zhou, Ph.D.

Assistant Professor

School: Medical School
Department: Radiation Oncology

Publications

DCR2-targeted ultrasound nanobubbles loaded with verteporfin promote M2 macrophage polarization to overcome doxorubicin resistance in breast cancer: Guo S, Zhang Y, Wang Y, Guo T, Zhu J, Chang L, Ling W, Westover KD, Zhou Z, Wei X Chemical Engineering Journal 2025 Feb 505
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118: Kramer-Drauberg M, Petrini E, Mira A, Patrucco E, Scardaci R, Savinelli I, Wang H, Qiao K, Carrà G, Nokin MJ, Zhou Z, Westover KD, Santamaria D, Porporato PE, Ambrogio C Molecular oncology 2025 Feb 19 311-328
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia: Chen Y, Yin Z, Westover KD, Zhou Z, Shu L Molecular Cancer Therapeutics 2025 Jan 24 33-46
Experimental variables determine the outcome of RAS-RAS interactions: Zhou Z, Nguyen TL, Li X, Poujol C, Berlinska E, Michelina SV, Kapp JN, Plückthun A, Winslow MM, Ambrogio C, Shan Y, Santamaría D, Westover KD Journal of Biological Chemistry 2024 Nov 300
GLUT3 promotes macrophage signaling and function via RAS-mediated endocytosis in atopic dermatitis and wound healing: Yu DM, Zhao J, Lee EE, Kim D, Mahapatra R, Rose EK, Zhou Z, Hosler C, El Kurdi A, Choe JY, Abel ED, Hoxhaj G, Westover KD, Cho RJ, Cheng JB, Wang RC Journal of Clinical Investigation 2023 Nov 133
Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer: Chen X, Li Y, Zhou Z, Zhang Y, Chang L, Gao X, Li Q, Luo H, Westover KD, Zhu J, Wei X Cancer Medicine 2023 Oct 12 19904-19920
Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families: Li L, Meyer C, Zhou ZW, Elmezayen A, Westover K Journal of Molecular Biology 2022 Sep 434
PD-L1^P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer: Li Q, Zhou ZW, Lu J, Luo H, Wang SN, Peng Y, Deng MS, Song GB, Wang JM, Wei X, Wang D, Westover KD, Xu CX Molecular Therapy 2022 Feb 30 621-631
CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma: Zi D, Li Q, Xu Cx, Zhou ZW, Song GB, Hu CB, Wen F, Yang HL, Nie L, Zhao X, Tan J, Zhou SF, He ZX Aging 2022 14 4673-4698
Correction: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma, (Aging (Albany NY), (2022), 14(11), (4673–4698), (10.18632/aging.203241)): Zi D, Li Q, Xu Cx, Zhou ZW, Song GB, Hu CB, Wen F, Yang HL, Nie L, Zhao X, Tan J, Zhou SF, He ZX Aging 2022 14 8876-8878